Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Ensayo de flujo lateral basado en amplificación isotérmica para la detección y diferenciación simultáneas de los virus del Dengue y Zika


Oferta Tecnológica
Un hospital de Singapur ha desarrollado un ensayo de flujo lateral basado en amplificación isotérmica para la detección de los virus del Dengue (DENV) y Zika (ZIKV). Este ensayo simplifica el procesamiento de muestras y la amplificación isotérmica de secuencias objetivo en el ARN de los virus del Dengue y Zika, ayudando a detectar y diferenciar los virus. Los resultados son visualizados en una tira de ensayo basado en flujo lateral como líneas de prueba y control. El hospital busca pymes, multinacionales o centros de investigación con el fin de establecer acuerdos de licencia e I+D.


Isothermal amplification-based lateral flow test for simultaneous detection and distinction of Zika and Dengue infections
A Singapore hospital has developed an isothermal amplification-based lateral flow test to detect the Dengue (DENV) and/or Zika (ZIKV) virus. It streamlines sample processing and isothermal amplification of target sequences in DENV and/or ZIKV viral RNA which helps in detection and differentiation of DENV and ZIKV viruses. Results are visualized on a lateral flow-based test strip as test and control lines.

The hospital seeks licensing/R-Y-D partnerships with SMEs, MNEs or research institutions.
Flaviviral infections are on the rise globally, and are causing human diseases such as dengue, Chikungunya and fatal Zika infections. These viruses (DENV, ZIKV) viruses are transmitted via the same Aedes mosquito vector. All flaviviral infections are closely related and have similar clinical symptoms such as high fever, muscle and joint pain, retro-orbital pain and skin rash.

Accurate disease diagnosis is challenging. This new invention is a fast, reliable and accurate tool for differential diagnosis that can help in early diagnosis of infectious diseases, and enable early medical intervention for efficient disease management. Such point-of-care diagnosis can help reduce diagnosis pressure on public health, and help authorities in managing current and future viral outbreaks.

This point-of-care isothermal amplification-based lateral flow test detects and differentiates between closely related dengue and Zika viral infections. This diagnostic technology comprises three main components.

First, blood samples from patients are taken, and live viruses present in these samples are broken down to release the viral RNA and specific probe-primer sets.

After releasing the viral RNA, it undergoes one-step reverse transcription-recombinase-polymerase amplification (RT-RPA) reaction for the amplification of DENV- and ZIKV-specific target sequences. This isothermal amplification reaction is conducted in a closed system at a constant temperature for few minutes time frame.

Finally, the isothermal amplification reaction volume is analysed on a lateral flow-based test strip platform. The amplified RT-RPA samples can be diluted and applied on the sample port and by lateral flow the reaction volume is drawn across the strip, thereby forming control and test lines depending upon the presence or absence of DENV and/or ZIKA viruses.

The hospital is interested in establishing license agreements and research cooperation agreements with partner from the healthcare industry, such as an SME of any size or and MNE to commercialise the technology, or with a research institute for further R-Y-D.
Advantages and Innovations:
This point of care differential diagnostic test can be used in clinics and hospitals for diagnosing dengue and Zika viral infections. This test can help in assessing the distribution of DENV and ZIKV virus during on-site breeding site monitoring.

One of the primary advantages of this diagnostic technology is that since specific probe-primer set design determines the target identity of the test, this same technology can be used to test a wide range of DNA and/or RNA targets.

The other advantage of this differential diagnostic test is that it adopts RPA-lateral flow over the established Polymerase Chain Reaction (PCR) method, thus causing significant benefits. RPA requires less than 2 hours, which is much faster than PCR which requires approximately 3-4 hours.
RPA-lateral flow requires a single constant temperature condition (37-39°C), whereas PCR requires varying temperatures (55°C-95°C) at different phases of the cycle. The RPA-lateral flow technology is easy to conduct and read. PCR analysis requires trained personnel for reaction preparation and PCR results analysis, thereby limiting its use to laboratory setting. However, the RPA-lateral flow technology is simple to use and read. It can be used easily on field and at home. The results can be easily read on the lateral flow test strips by checking the presence/absence of test lines and control lines.

The traditional PCR system is extremely expensive, requiring heavy equipment (thermocycler with/without quantitative detector module). In comparison, RPA-lateral flow total costs including a simple heat block and detection strip makes it highly economical. This test is highly important for geographical regions where sophisticated and costly laboratory facilities are not available.
Stage of Development:
Prototype available for demonstration
Patents granted
CommeR Statunts Regarding IPR Status:
Patents granted for Singapore. Technology is available for licensing.

Partner sought

Type and Role of Partner Sought:
The Singapore hospital seeks to work with SMEs of all sizes, MNEs or research/healthcare institutions in a licensing or research cooperation agreement partnership.

The partner sought could be a healthcare institution or healthcare technologies provider.

Under a licensing agreement:
The partner can license the technology to offer as a product or service to their customers.

Under a research cooperation agreement:
The partner can undertake joint development with the Singapore hospital to offer to introduce new products to targeted markets/segments.


Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
Languages Spoken:


Technology Keywords:
06001005 Diagnósticos, diagnosis